Cybin announces initiation of kernel flow® feasibility study measuring psychedelic effects on the brain

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (cybin or the company), a biopharmaceutical company focused on progressing “psychedelics to therapeuticstm”, today announced that the first study visit has been conducted in a cybin-sponsored feasibility study evaluating kernel's quantitative neuroimaging technology, flow, to measure ketamine's psychedelic effects on cerebral cortex hemodynamics. “the commencement of the kernel feasibility study marks a truly exciting moment,
CYBN Ratings Summary
CYBN Quant Ranking